

1 Use of tryptic peptide MALDI mass spectrometry imaging to identify the spatial 2 proteomic landscape of colorectal cancer liver metastases.

3
4 *Celine Man Ying Li^{1,2}, *Matthew T Briggs³, Yea-Rin Lee³, Teresa Tin², Clifford Young³, John Pierides⁴,
5 Gurjeet Kaur⁵, Paul Drew^{1,2}, Guy J Maddern^{1,2}, Peter Hoffmann³, Manuela Klingler-Hoffmann^{3#} and Kevin
6 Fenix^{1,2#}

7 ^{1.} Discipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, SA 5005, Australia.

8 ^{2.} The Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Adelaide, SA
9 5011, Australia.

10 ^{3.} Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, 5000, Australia.

11 ^{4.} SA Pathology, Royal Adelaide Hospital, Adelaide, SA, 5000, Australia

12 ^{5.} Institute for Research in Molecular Medicine, University Sains Malaysia, Pulau Pinang, 11800, Malaysia

13 (*) equal contribution.

14 #Correspondence: manuela.klingler-hoffmann@unisa.edu.au and kevin.fenix@adelaide.edu.au

15
16 **Keywords:** Colorectal cancer liver metastasis, MALDI-MSI, LC-MS/MS, biomarkers, drug targets, colorectal
17 cancer

18 19 **Abstract**

20
21 Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. CRC liver metastases
22 (CRLM) are often resistant to conventional treatments, with high rates of recurrence. Therefore, it is crucial to
23 identify biomarkers for CRLM patients that predict cancer progression. This study utilised matrix-assisted laser
24 desorption/ionisation mass spectrometry imaging (MALDI-MSI) in combination with liquid chromatography-
25 tandem mass spectrometry (LC-MS/MS) to spatially map the CRLM tumour proteome. CRLM tissue
26 microarrays (TMAs) of 84 patients were analysed using tryptic peptide MALDI-MSI to spatially monitor
27 peptide abundances across CRLM tissues. Abundance of peptides was compared between tumour vs stroma,
28 male vs female and across three groups of patients based on overall survival (0-3 years, 4-6 years, and 7+ years).
29 Peptides were then characterised and matched using LC-MS/MS. A total of 471 potential peptides were
30 identified by MALDI-MSI. Our results show that two unidentified *m/z* values (1589.876 and 1092.727) had
31 significantly higher intensities in tumours compared to stroma. Ten *m/z* values were identified to have
32 correlation with biological sex. Survival analysis identified three peptides (Histone H4, Hemoglobin subunit
33 alpha, and Inosine-5'-monophosphate dehydrogenase 2) and two unidentified *m/z* values (1305.840 and
34 1661.060) that were significantly higher in patients with shorter survival (0-3 years relative to 4-6 years and 7+
35 years). This is the first study using MALDI-MSI, combined with LC-MS/MS, on a large cohort of CRLM
36 patients to identify the spatial proteome in this malignancy. Further, we identify several protein candidates that
37 may be suitable for drug targeting or for future prognostic biomarker development.

41

42 **Introduction**

43

44 Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths
45 worldwide [1]. Approximately 50% of CRC cases metastasise to the liver [2]. CRC liver metastasis (CRLM) is
46 normally treated with surgical resection and chemotherapy. However, most CRLM cases present with multiple
47 liver metastases or have patients with poor health conditions that prevents surgery [3]. Most CRLMs ultimately
48 develop chemo-resistance [4]. Even with curative intent, CRLM has a relapse rate of 50% [5]. Together these
49 factors contribute to CRLM having a 5-year survival rate of 30% [2]. Currently, there are no predictive
50 biomarkers for CRLM recurrence or survival. CRLM surveillance currently involves frequent computed
51 tomographic (CT) scans and monitoring for blood carcinoembryonic antigen (CEA) levels [6, 7]. However,
52 these surveillance strategies have failed to detect early relapse, contributing to disease progression. Thus, there
53 is an urgent need for predictive markers for CRLM survival [5].

54

55 Quantitative image analysis for tissue histological biomarkers based on routine histochemistry or
56 immunohistochemistry has been used for clinical diagnostics and biomarker research [8]. In cancer research,
57 recent advances in mass spectrometry have made proteomics a useful approach for biomarker discovery [9, 10].
58 In particular, matrix-assisted laser desorption/ionisation (MALDI) mass spectrometry imaging (MSI) generates
59 unbiased spatial intensity maps of molecules such as intact proteins, tryptic peptides, *N*-glycans, lipids or
60 metabolites, which allows for the spatial mapping of tumour tissues. MALDI-MSI has been demonstrated to
61 predict metastatic potential, disease recurrence, and survival in variety of primary cancers [11-13].

62

63 In the context of CRC, MALDI-MSI has been extensively applied to primary tumours and has identified
64 prognostic indicators for overall survival [14-16]. For example, multiple analytes have been shown to be
65 associated with clinical outcomes such as tumour stage, grade, metastasis, and cancer cell proliferation in
66 primary CRC. However, there are a limited number of MALDI-MSI studies on CRLM. To the best of our
67 knowledge, only two reports have applied MALDI-MSI to detect lipid [17] and phospholipid [18] signatures on
68 CRLM tissue. These studies identified tumour localised lipid signatures that could have prognostic potential or
69 can be therapeutic targets. Whereas two additional MALDI-MSI studies identified the spatial proteome with
70 limited sample sizes preventing any correlation with survival [19, 20].

71

72 In this study, we applied tryptic peptide MALDI-MSI on a cohort of Australian CRLM patients and identified
73 peptides that discriminate between tumour features, patient characteristics, and survival outcomes. Subsequently,
74 liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed on tryptic peptides obtained
75 from consecutive tissue sections to identify the associated proteins [21]. We identified discriminative proteins
76 related to tumour features, and potential prognostic biomarkers that were associated with worse clinical
77 outcomes in CRLM patients.

78

79 **Material and Methods**

80

81 ***Sample Collection and Tissue Specimens***

82

83 A retrospective cohort of CRC patients with liver metastases were identified using the South Australian
84 Metastatic Colorectal Cancer Registry (SAMCRC) [22]. From that cohort, patients who had undergone liver
85 resection were selected for the study. Their corresponding FFPE tissue blocks were retrieved from SA
86 Pathology sites based at The Queen Elizabeth Hospital, Royal Adelaide Hospital and Flinders Medical Centre,
87 Adelaide, South Australia. Retrieved cases were reviewed by a clinical pathologist (J.P) for study suitability.
88 Demographics and clinicopathological characteristics of patients were shown in Table 1. This study was
89 approved by the Human Research Ethics Committee of the Central Adelaide Local Health Network under
90 protocol number 12237.

91

92 ***Tissue Microarray Construction***

93

94 Previously selected tissue blocks were annotated by a pathologist (J.P), clearly distinguishing regions with
95 viable tumours from normal liver. Two tumour cores and one normal liver core per patient were inserted into the
96 TMA recipient block. Four TMA blocks were analysed, totalling 168 CRLM tumour cores from 84 patients.
97 TMAs were constructed using a TMA Master II (3DHISTECH, Budapest, Hungary). The completed block was
98 sealed with paraffin and stored at 4°C.

99

100 ***Hematoxylin and Eosin (H&E) Staining***

101

102 FFPE tissue blocks were cut by microtome into 6 µm sections. They were first deparaffinized and rehydrated
103 with xylene for 3 x 5 mins, dipped in ethanol (100%) for 3 x 4 mins, ethanol (90%, v/v) for 2 mins, ethanol
104 (70%, v/v) for 2 mins, and washed with distilled water for 1 min. Subsequently, slides were stained with
105 hematoxylin for 5 mins, then washed with running tap water for 5 mins. Slides were then dipped into 0.3%
106 hydrochloric acid with ethanol (75%, v/v) for 10 seconds, followed by washing with tap water for 10 mins.
107 Tissues were stained with eosin for 1 min and washed with ethanol (100%) for 1 min. The H&E-stained TMA
108 slides were scanned by a NanoZoomer 1 Digital Slide Scanner (Hamamatsu Photonics K.K, Japan). Images
109 were acquired and viewed using NDP.view2 software (Hamamatsu).

110

111 ***Tryptic Peptide MALDI-MSI Sample Preparation***

112

113 Tryptic peptide MALDI-MSI was performed on the sectioned TMAs following the protocol as previously
114 described, with minor modifications [23]. Briefly, 6 µm sectioned TMAs on indium tin oxide (ITO) slides were
115 washed with RCL premium grade xylene (100%) for 2 x 5 min, HPLC grade ethanol (100%) for 2 x 2 min, and
116 10 mM ammonium bicarbonate for 2 x 5 min. Slides were then boiled with 10 mM citric acid (pH 6) in a
117 conventional microwave (1250 W, Model MS2540SR, LG, China), followed by pulse-heating for 10 min and
118 heating at 98 °C on a heating block for 30 min. Slides were cooled down at room temperature prior to washing
119 with 10 mM ammonium bicarbonate for 2 x 1 min. Subsequently, slides were dried at ambient conditions,

120 marked with a water-based white-out, and scanned using a flattop scanner (Epson Perfection V600 Photo,
121 Model J25A, Epson, Indonesia) to teach the instrument during MALDI-MSI data acquisition.

122

123 Next, 20 μg of trypsin gold (Promega) in 200 μL of 25 mM ammonium bicarbonate and acetonitrile (10%, v/v)
124 was deposited onto slides using an ImagePrep instrument (Bruker Daltonic, Germany) in 30 cycles with a fix
125 nebulization time of 1.2 sec and drying time of 15 sec followed by incubation at 37 °C for 2 h in a humidified
126 chamber containing potassium sulphate (53.3 g) and MilliQ water (18.2 g). Next, 7 mg/mL of alpha-cyano-4-
127 hydroxycinnamic acid (HCCA) in acetonitrile (50%, v/v) and trifluoroacetic acid (TFA, 0.2%, v/v) was
128 deposited onto slides using an iMatrix Spray instrument (Tardo, Switzerland). Instrument-specific settings were
129 as follows: 60 mm height, 1 mm line distance, 180 mm/s speed, 1 $\mu\text{L}/\text{cm}^2$ density, 30 cycles and 15 sec delays.

130

131 ***MALDI-MSI Data Acquisition***

132

133 MALDI-MSI data was acquired on a timsTOF fleX MS instrument (Bruker Daltonic, Germany), controlled by
134 timsControl (v3.0, Bruker Daltonics) and flexImaging (v7.0, Bruker Daltonics) in positive mode in the mass
135 range of m/z 700-3200. The instrument was calibrated using an internal calibrant [24]. Instrument-specific
136 settings were as follows: a transfer time of 180 μs , a pre-pulse storage of 25 μs , a collision RF of 4000 Vpp, a
137 collision energy of 10 eV, a funnel 1 (accumulation) RF of 500 Vpp, a funnel 2 (analysis) RF of 500 Vpp, a
138 multipole RF of 500 Vpp and a quadrupole ion energy of 5 eV. Laser power was set at 60% and pixel resolution
139 at 50 μm .

140

141 ***MALDI-MSI Data Analysis***

142

143 MALDI-MSI data was imported into SCiLS Lab v2023a (Bruker Daltonics, Germany) and pre-processed by
144 TopHat baseline subtraction and root mean square (RMS) normalisation. Individual TMA cores were annotated
145 based on pathological annotations by a pathologist (G.K.) from consecutive H&E-stained images scanned with
146 NanoZoomer (Hamamatsu). The feature finding tools were then used to create a list of putative peptides. The
147 feature finding uses the T-Rex² algorithm, and very strong filtering with 5% coverage and 0.5% relative
148 intensity threshold were applied. For comparisons of peak intensities between the groups, the RMS normalised
149 average spectra of each mass was exported as Excel files and statistical analysis performed using GraphPad
150 Prism (v 9.0, San Diego, CA).

151

152 ***LC-MS/MS Sample Preparation***

153

154 CRLM TMAs were sectioned using a microtome (Microm HM 325) at 6 μm thickness and placed directly into
155 1.5 mL Eppendorf Protein LoBind Tubes. Paraffin was removed by the addition of 100 μL of xylene (100%) for
156 2 min and 100 μL of ethanol (100%) for 2 min. Sections were then rehydrated by the addition of 100 μL of
157 Milli-Q water (100%) for 2 x 2 min and 100 μL of 50 mM ammonium bicarbonate (100%) for 2 x 2 min. Then
158 the tissue was boiled in 30 μL of 10 mM citric acid at pH 6 at 98 °C for 20 min in a Thermomixer (1500 rpm),
159 followed by 80 °C for 2 h. Tubes were cooled to room temperature and then centrifuged at 20,000 x g and 4 °C

160 for 30 min. Proteins were denatured from the tissue by adding 30 μ L of 8 M urea, followed by incubation at
161 room temperature for 30 min. Subsequently, samples were analysed using a modified tryptophan assay to
162 determine protein concentrations [25].

163

164 Protein reduction was by incubation with 2.5 μ L of 0.2 M dithiothreitol (DTT) at room temperature for 1 hr on a
165 Thermomixer (500 rpm). Proteins were then alkylated by the addition of 2.8 μ L of 0.275 M 2-chloroacetamide
166 (CA) and incubation in the dark for 30 min on a shaking Thermomixer. Protein digestion was performed with
167 sequencing grade trypsin (Promega, USA) (1:50) at 37 °C overnight on a shaking Thermomixer, with digestion
168 stopped by the addition of 10% formic acid (5 μ L). Finally, tryptic peptides were desalted using C18 ZipTips
169 (Millipore, Ireland) according to the manufacturer's instructions.

170

171 *LC-MS/MS Data Acquisition*

172

173 LC-MS/MS analysis was conducted on an EASY-nLC 1200 system coupled to an Orbitrap Exploris 480 mass
174 spectrometer (Thermo Scientific, Bremen, Germany). Peptides (approximately 500 ng) were resuspended in 0.1%
175 formic acid and loaded onto a 25 cm fused silica column (75 μ m inner diameter, 360 μ m outer diameter) heated
176 to 50 °C. The column was packed with 1.9 μ m ReproSil-Pur 120 C18-AQ particles (Dr. Maisch, Ammerbuch,
177 Germany). Peptides were separated over a 30 min linear gradient (3 to 24% acetonitrile in 0.1% formic acid) at a
178 flow rate of 300 nL/min. A compensation voltage of -45 V was applied from a FAIMS Pro interface (Thermo
179 Scientific) to minimise the impact of interfering ions before implementing a data-independent acquisition (DIA)
180 MS method. Briefly, an MS scan (m/z 395 to 905) was acquired at resolution 30000 (m/z 200) in positive ion
181 mode before isolated precursors (50 x 10 m/z windows, 1 m/z overlap) were fragmented with higher energy
182 collision dissociation (27.5% normalised collision energy). The resulting MS/MS spectra (m/z 145 to 1450)
183 were measured at resolution 22500.

184

185 *LC-MS/MS Data Analysis*

186

187 Raw data files were processed with Spectronaut v17.4.230317 (Biognosys AG, Schlieren, Switzerland). A direct
188 DIA+ analysis was conducted by searching a UniProt human proteome database (Release 2022_04, 20607
189 canonical entries) with BGS factory settings. We manually matched single charged m/z values obtained from the
190 MALDI-MSI data with singly charged m/z values calculated from doubly or triply charged peptides identified
191 using Spectronaut analysis peptides with a peptide tolerance of +/- 16 ppm.

192

193 **Results**

194

195 *Identification of tryptic peptide signatures in CRLM samples using MALDI-MSI.*

196

197 To identify tryptic peptides associated with CRLM, we first constructed four TMAs from 84 CRLM patients
198 consisting of 168 CRLM tumour tissue cores (two per patient, Table 1). The TMAs were sectioned onto
199 conductive ITO slides and prepared for MALDI-MSI analysis. A comprehensive and detailed MALDI-MSI

200 workflow is presented in Fig. 1A. For the analysis of the processed MALDI-MSI data, tumour cores were
201 annotated as tumour (cancer cell rich) and intratumoral stroma (cancer cell poor/free) regions in SCiLS Lab by
202 matching pathologist annotated H&E regions overlaid with the MALDI-MSI optical image (Fig. 2).
203 Subsequently, the feature finding tool in SCiLS Lab was used to generate a list of 471 putative peptides by
204 applying very strong filtering with 5% coverage and 0.5% relative intensity threshold. Next, the receiver
205 operating curve (ROC) discriminating feature tool was used to identify m/z values with the highest area under
206 the curve (AUC) when comparing between tumour and stroma, male and female patients and across three
207 groups of patients' overall survival (0-3 years, 4-6 years, and 7+ years). Furthermore, denatured proteins from
208 consecutive tissue sections were then digested in-solution into tryptic peptides for LC-MS/MS analysis to
209 identify proteins by matching peptide sequences with measured m/z values by MALDI-MSI (Fig. 1B). To
210 achieve an extensive list of peptides identified by LC-MS/MS, the raw data was analysed in Spectronaut and
211 resulted in the identification of 3332 proteins from CRLM samples.

212

213 *Identification of tryptic peptides associated with CRLM tumour regions.*

214

215 First, to identify tryptic peptides that significantly distinguished between tumour and stroma, we selected
216 MALDI-MSI m/z values with the highest AUC values to discriminate the two regions. From this analysis, 20
217 m/z values had AUC values of >0.5 which were then investigated further if they have significant abundances in
218 the CRLM tissues (Table 2). The 20 m/z values were observed between a m/z range of 1000 to 2300 (Fig. 3A-B).
219 Subsequently, a ROC plot with associated AUC values for each peptide was generated to plot the specificity and
220 sensitivity in relation to tumour and stroma. Of the 20 m/z values, m/z 1589.876 with 0.618 AUC (95% CI:
221 0.563-0.674), and m/z 1092.727 with 0.562 AUC (95% CI: 0.504-0.620) were found to be high in intensity in
222 tumour regions relative to stroma regions. Unfortunately, m/z 1589.876 and m/z 1092.727 could not be
223 identified from the LC-MS/MS data (Fig. 3C-F). The remaining 18 m/z values with AUC values >0.5 were not
224 statistically significant (Table 2 and Supp. Fig 1).

225

226 *Identification of tryptic peptides associated with biological sex.*

227

228 Next, we determined if there were differences in the spatial proteome between male and female CRLM tumour
229 tissues. Selecting, MALDI-MSI peaks with an AUC of >0.5 resulted in the identification of 14 m/z values. From
230 this analysis, 8 m/z values (m/z 2211.113, 1296.682, 1570.676, 1669.829, 1461.702, 1465.697, 1235.618, and
231 1366.628) were found to be significantly different in the tumour region between males and females with AUC
232 values between 0.600-0.695 (Table 3 and Supp. Fig. 2). Interestingly, we identified 4 (m/z 2211.113, 1296.682,
233 1570.676, 1366.628) to be higher in intensity in females (Fig 4A-D), whereas another 4 (m/z 1669.829,
234 1461.702, 1465.697, 1235.618) were higher in intensity in males (Fig. 4E-H). In the stroma (Supp. Fig. 3), 8
235 (m/z 2211.113, 1296.682, 1570.676, 1669.829, 1465.697, 1366.628, 1661.060 and 1305.840) were identified to
236 be statistically different between male and females, with 6 (m/z 2211.113, 1296.682, 1570.676, 1366.628,
237 1661.060 and 1305.840) higher in females (Fig 5A-F) compared to 2 (m/z 1669.829 and 1465.697) in males (Fig
238 5G-H). The AUC values ranged from 0.633-0.677.

239

240 In total 10 unique m/z values were identified to discriminate between male and female tissues (Table 3). Six of
241 the 10 m/z values were associated with biological sex regardless of the region type (tumour or stroma). Using
242 LC-MS/MS, we identified 3 peptides, [FTTDAIALAMSR] (m/z 1296.682) from Proteasome subunit beta type-9
243 (PSMB9), [SDLVNEEATGQFR] (m/z 1465.697) from Carcinoembryonic antigen-related cell adhesion
244 molecule 5 (CEACAM5), and [YHLGAYTGDDVR] (m/z 1366.628) from Tryptase beta-2 (TPSB2) or Tryptase
245 alpha/beta-1 (TPSAB1), while the corresponding peptides for m/z 2211.113, m/z 1570.676 and m/z 1669.829
246 could not be identified. Further, an unidentified m/z value (m/z 1461.702) and [MVNHFIAEFK] (m/z 1235.618)
247 from Heat shock cognate 71 kDa protein (HSPA8) were higher in male tumour regions, while two unidentified
248 m/z values (1661.060 and 1305.840) were higher in female stroma regions. Together, these results indicated that
249 biological sex could contribute to changes to both the overall and region-specific tumour proteome.

250

251 *Identification tryptic peptides linked to survival.*

252

253 To identify potential prognostic markers for CRLM, we classified our patient cohort into 3 groups based on
254 survival (0-3 years, 4-6 years, and 7+ years). Specific to the tumour region (Supp. Fig 4), we identified 6 m/z
255 values that had an AUC >0.5 between 0-3 and 7+ years survival. From this list, 5 m/z values (m/z 1325.754,
256 1529.738, 1481.857, 1305.840 and 1661.060) achieved statistical significance (Table 4). [DNIQGITKPAIR]
257 (m/z 1325.754) from histone H4 had the highest AUC value of 0.720 (95% CI: 0.6320-0.8086) (Fig. 6A).
258 Additionally, [VGAHAGEYGAEALER] (m/z 1529.738) from Haemoglobin subunit alpha (HBA1),
259 [REDLVVAPAGITLK] (m/z 1481.857) from Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2), and 2
260 unidentified m/z values (m/z 1305.840 and 1661.060) were all relatively high abundant in patients who had poor
261 survival outcomes (0-3 years post-surgery) compared to those who have survived for 7 or more years (Fig. 6).
262 Analysing the stromal regions (Supp. Fig. 5), only histone H4 replicated the tumour analysis showing higher
263 abundance in patients with poor (0-3 years) survival outcomes (Supp. Fig. 6). Together, our MALDI-MSI
264 analysis identified peptides that associated with duration of survival in CRLM patients.

265

266 **Discussion**

267

268 CRLM is a highly lethal and heterogeneous disease with poor prognostic tests available [26, 27]. While previous
269 studies have reported on the use of MALDI-MSI in CRLM tissue, most have used small sample sizes to only
270 describe the proteomic landscape of CRLM [19, 20]. To the best of our knowledge, this study is the first study
271 to utilise MALDI-MSI combined with LC-MS/MS to identify potential protein biomarkers in CRLM patients.
272 Furthermore, we applied this technology on the largest cohort of CRLM patients collected in Australia.

273

274 The tumour-stroma ratio is a well-known independent prognostic indicator for CRC, with high levels of stroma
275 associating with poor survival [28, 29]. Thus, we determined if there are consensus proteins that could
276 discriminate between the two regions in our heterogeneous CRLM sample cohort by MALDI-MSI. MALDI-MSI
277 analysis between tumour and intratumoral stroma regions, identified peptides that associate with tumour regions.
278 Among the 20 m/z values identified using MALDI-MSI, 2 (m/z 1589.876 and 1092.727) reached statistical

279 significance, however it was not possible to establish matches with our LC-MS/MS data. Nevertheless, our
280 MALDI-MSI data was able to find features that distinguish tumours from stroma.

281

282 While it is widely appreciated that biological sex can greatly affect cancer biology and treatment outcomes [30,
283 31], proteomic analyses that describe such contributions, especially in CRLM, are rarely reported. In this study,
284 we investigated if biological sex was associated with differences in the spatial proteome of CRLM. We
285 identified PSMB9, CEACAM5 and TPSB2/TPSAB1 and 3 unidentified m/z values (m/z 2211.113, 1570.676
286 and 1669.829) that had significant differences in abundance between male and female CRLM tissues. These
287 were sex-specific for both tumour and stroma regions. Interestingly, HSPA8 and an unidentified m/z value (m/z
288 1461.702) localised to tumours specific to males, and 2 unidentified m/z values (m/z 1305.840 and 1661.060)
289 localised to stroma, that were specific to females. Together these results show for the first time that biological
290 sex may have an underappreciated role in the spatial proteome of CRLM that may have currently unknown
291 consequences to its pathophysiology. Further research is required to determine if expression of these proteins
292 affect sex specific CRLM progression and treatment outcomes.

293

294 We report that histone H4, HBA1, IMPDH2, and two unidentified m/z values (m/z 1305.840 and 1661.060) are
295 more abundant in tumour tissues of CRLM patients with poor survival. In this study, only histone H4 expression
296 in tumour and/or stroma was enriched in patients that survived for >3 years. Histones are key epigenetic
297 regulators. Their post-translational modifications (acetylation, methylation and phosphorylation) can be linked
298 with gene expression changes that lead to cancer progression including CRC and hence are being investigated
299 for their therapeutic and prognostic potential [32]. Histone H4 upregulation has been linked to platinum-based
300 chemotherapy resistance in malignancies [33] and may explain its association with poor prognosis in our patient
301 cohort. Interestingly, histone H4 was identified to be elevated in CRC patient plasma by mass spectrometry
302 (detecting the [DNIQGITKPAI] peptide sequence) [34], and ELISA [35]. Thus, histone H4 could potentially be
303 developed as a blood biomarker to identify CRLM patients with worse prognostic outcomes. The relationship
304 between histone H4 tumour tissue expression, plasma levels, and survival outcomes is unknown and warrants
305 further investigation. HBA1 is the alpha subunit of hemoglobin. Anaemia, measured by blood hemoglobin
306 levels, has been linked with tumour hypoxia and poor outcomes in solid tumours [36]. However, the specific
307 contribution of HBA1 in cancer progression is unknown. Recent single cell RNA-sequencing analysis of gastric
308 cancers shows that HBA1 is overexpressed in gastric cancer cells. Importantly, patients with high tumour HBA1
309 expression led to poor overall survival supporting our findings in CRLM [37]. The contributions of IMPDH2 in
310 CRC progression is well established. IMPDH2 is an isoform of IMPDH, an enzyme critical for biosynthesis of
311 purine nucleotides and is essential for DNA synthesis [38]. IMPDH2 is commonly upregulated in malignancies
312 [39] including primary CRC [40]. IMPDH2 has been shown to promote CRC tumorigenesis [41], metastatic
313 potential [42] and in methotrexate resistance [43]. Thus, IMPDH2 has been previously implied as a potential
314 prognostic marker for CRC outcomes and may be useful as a drug target. Collectively, our study identified
315 previously reported and novel tryptic peptides candidates that may be able to predict poor outcomes in CRLM
316 patients. Considering the reported function of these proteins in cancer, these may also be used as novel targets in
317 CRLM therapy development.

318

319 In this study we used a manual indirect identification approach, where we matched the MALDI-MSI data with
320 data from an independent LC-MS/MS experiment. As part of this workflow, we have implemented internal
321 calibrants to allow high accuracy peptide matching [24]. However, there are limitations in this study to consider,
322 including the identification of peptides with the similar m/z values which fit within the same MALDI-MSI mass
323 tolerance window, therefore potentially resulting in mis-assignments. Additional validation by *in situ* tandem
324 MS fragmentation to confirm the identity of the peptides may improve peptide identification [44]. However, this
325 approach is only feasible for peptides with high signal intensity. Recently, several automated annotation tools
326 have been developed, which even include post-translational modifications [24, 45]. These tools might be used to
327 identify more of the 471 peptides from the LC-MS/MS data. Moreover, additional methods such as
328 immunohistochemistry could be employed to validate the abundance of the identified proteins in the metastatic
329 tumour regions. A second independent cohort of patients is required to validate our findings and confirm the
330 prognostic potential of the identified proteins that associated with poor CRLM survival outcomes. Nonetheless,
331 this study provides novel and valuable insights into CRLM biology and identifies potential prognostic
332 biomarkers and targets that are needed in CRLM.

333

334 **Conclusions**

335

336 In summary, this is the first study to utilise MALDI-MSI with LC-MS/MS to identify potential spatial
337 proteomic tissue biomarkers in the largest cohort of Australian CRLM patients to date. Using these workflows,
338 spatial proteomic features present in CRLM were revealed and changes within the tumour proteome identified in
339 relation to clinical features, including sex and overall survival. Importantly, we reveal that biological sex could
340 impact the spatial proteome profile of CRLM tumours and identified several proteins that associate with poor
341 survival in CRLM patients. These findings should be further explored to identify new prognostic markers and
342 therapeutic targets that are highly needed in CRLM.

343

344 **References**

- 345 [1] E. Morgan *et al.*, "Global burden of colorectal cancer in 2020 and 2040: incidence and
346 mortality estimates from GLOBOCAN," *Gut*, vol. 72, no. 2, pp. 338-344, 2023, doi:
347 10.1136/gutjnl-2022-327736.
- 348 [2] H. Zhou *et al.*, "Colorectal liver metastasis: molecular mechanism and interventional
349 therapy," *Signal Transduction and Targeted Therapy*, vol. 7, no. 1, p. 70, 2022/03/04 2022,
350 doi: 10.1038/s41392-022-00922-2.
- 351 [3] Y. Dong and T. Gruenberger, "Surgical management of colorectal liver metastases—
352 a practical clinical approach," *European Surgery*, vol. 55, no. 3, pp. 94-99, 2023/06/01 2023,
353 doi: 10.1007/s10353-023-00796-w.
- 354 [4] H. Zhou *et al.*, "Colorectal liver metastasis: molecular mechanism and interventional
355 therapy," (in eng), *Signal Transduct Target Ther*, vol. 7, no. 1, p. 70, Mar 4 2022, doi:
356 10.1038/s41392-022-00922-2.
- 357 [5] T. Reinert *et al.*, "Circulating tumor DNA for prognosis assessment and postoperative
358 management after curative-intent resection of colorectal liver metastases," (in eng),
359 *International journal of cancer*, vol. 150, no. 9, pp. 1537-1548, May 1 2022, doi:
360 10.1002/ijc.33924.
- 361 [6] J. H. Kang and S. H. Choi, "Imaging study for colorectal liver metastasis: beyond the
362 diagnosis and to the prognosis," (in eng), *Hepatobiliary Surg Nutr*, vol. 8, no. 6, pp. 666-668,
363 Dec 2019, doi: 10.21037/hbsn.2019.10.06.
- 364 [7] K. Sasaki *et al.*, "Pre-hepatectomy carcinoembryonic antigen (CEA) levels among patients
365 undergoing resection of colorectal liver metastases: do CEA levels still have prognostic
366 implications?," (in eng), *HPB : the official journal of the International Hepato Pancreato*
367 *Biliary Association*, vol. 18, no. 12, pp. 1000-1009, Dec 2016, doi:
368 10.1016/j.hpb.2016.09.004.
- 369 [8] H. Lee *et al.*, "Quantitative Proteomic Analysis Identifies AHNAK (Neuroblast
370 Differentiation-associated Protein AHNAK) as a Novel Candidate Biomarker for Bladder
371 Urothelial Carcinoma Diagnosis by Liquid-based Cytology," (in eng), *Mol Cell Proteomics*,
372 vol. 17, no. 9, pp. 1788-1802, Sep 2018, doi: 10.1074/mcp.RA118.000562.
- 373 [9] M. A. Reymond and W. Schlegel, "Proteomics in cancer," (in eng), *Adv Clin Chem*, vol. 44,
374 pp. 103-42, 2007, doi: 10.1016/s0065-2423(07)44004-5.
- 375 [10] Y. W. Kwon *et al.*, "Application of Proteomics in Cancer: Recent Trends and Approaches for
376 Biomarkers Discovery," (in English), *Frontiers in Medicine*, Review vol. 8, 2021-September-
377 22 2021, doi: 10.3389/fmed.2021.747333.
- 378 [11] K. L. Sheng, L. Kang, K. J. Pridham, L. E. Dunkenberger, Z. Sheng, and R. T. Varghese, "An
379 integrated approach to biomarker discovery reveals gene signatures highly predictive of
380 cancer progression," *Scientific reports*, vol. 10, no. 1, p. 21246, 2020/12/04 2020, doi:
381 10.1038/s41598-020-78126-3.
- 382 [12] S. Meding *et al.*, "Tissue-based proteomics reveals FXVD3, S100A11 and GSTM3 as novel
383 markers for regional lymph node metastasis in colon cancer," (in eng), *J Pathol*, vol. 228, no.
384 4, pp. 459-70, Dec 2012, doi: 10.1002/path.4021.
- 385 [13] A. C. Hristov *et al.*, "HMGA2 protein expression correlates with lymph node metastasis and
386 increased tumor grade in pancreatic ductal adenocarcinoma," *Modern Pathology*, vol. 22, no.
387 1, pp. 43-49, 2009/01/01 2009, doi: 10.1038/modpathol.2008.140.
- 388 [14] T. Gemoll, S. Strohkamp, K. Schillo, C. Thorns, and J. K. Habermann, "MALDI-imaging
389 reveals thymosin beta-4 as an independent prognostic marker for colorectal cancer,"
390 *Oncotarget*, vol. 6, no. 41, 2015. [Online]. Available:
391 <https://www.oncotarget.com/article/6103/text/>.
- 392 [15] A. Hinsch *et al.*, "MALDI imaging mass spectrometry reveals multiple clinically relevant
393 masses in colorectal cancer using large-scale tissue microarrays," *Journal of Mass*
394 *Spectrometry*, vol. 52, no. 3, pp. 165-173, 2017, doi: <https://doi.org/10.1002/jms.3916>.
- 395 [16] B. Martin *et al.*, "A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in
396 UICC Stage I/II Colon Cancer," (in eng), *Cancers*, vol. 13, no. 21, Oct 26 2021, doi:
397 10.3390/cancers13215371.

- 398 [17] N. H. Patterson *et al.*, "Assessment of pathological response to therapy using lipid mass
399 spectrometry imaging," *Scientific reports*, vol. 6, no. 1, p. 36814, 2016/11/14 2016, doi:
400 10.1038/srep36814.
- 401 [18] S. Shimma, Y. Sugiura, T. Hayasaka, Y. Hoshikawa, T. Noda, and M. Setou, "MALDI-based
402 imaging mass spectrometry revealed abnormal distribution of phospholipids in colon cancer
403 liver metastasis," *Journal of Chromatography B*, vol. 855, no. 1, pp. 98-103, 2007/08/01/
404 2007, doi: <https://doi.org/10.1016/j.jchromb.2007.02.037>.
- 405 [19] L. Moritz *et al.*, "Characterization of Spatial Heterogeneity in Metastasized Colorectal Cancer
406 by MALDI Imaging," in *Preprints*, ed: Preprints, 2023.
- 407 [20] A. Turtoi *et al.*, "Organized proteomic heterogeneity in colorectal cancer liver metastases and
408 implications for therapies," *Hepatology*, vol. 59, no. 3, pp. 924-934, 2014, doi:
409 <https://doi.org/10.1002/hep.26608>.
- 410 [21] R. Casadonte *et al.*, "Imaging mass spectrometry to discriminate breast from pancreatic
411 cancer metastasis in formalin-fixed paraffin-embedded tissues," (in eng), *Proteomics*, vol. 14,
412 no. 7-8, pp. 956-64, Apr 2014, doi: 10.1002/pmic.201300430.
- 413 [22] Y. Tomita *et al.*, "Survival improvements associated with access to biological agents: Results
414 from the South Australian (SA) metastatic colorectal cancer (mCRC) registry," *Acta
415 Oncologica*, vol. 55, no. 4, pp. 480-485, 2016/04/02 2016, doi:
416 10.3109/0284186X.2015.1117135.
- 417 [23] T. W. Powers *et al.*, "MALDI imaging mass spectrometry profiling of N-glycans in formalin-
418 fixed paraffin embedded clinical tissue blocks and tissue microarrays," (in eng), *PLoS One*,
419 vol. 9, no. 9, p. e106255, 2014, doi: 10.1371/journal.pone.0106255.
- 420 [24] J. O. R. Gustafsson *et al.*, "Internal calibrants allow high accuracy peptide matching between
421 MALDI imaging MS and LC-MS/MS," (in eng), *J Proteomics*, vol. 75, no. 16, pp. 5093-5105,
422 Aug 30 2012, doi: 10.1016/j.jprot.2012.04.054.
- 423 [25] J. R. Wiśniewski and F. Z. Gaugaz, "Fast and Sensitive Total Protein and Peptide Assays for
424 Proteomic Analysis," *Analytical Chemistry*, vol. 87, no. 8, pp. 4110-4116, 2015/04/21 2015,
425 doi: 10.1021/ac504689z.
- 426 [26] J. Guinney *et al.*, "The consensus molecular subtypes of colorectal cancer," *Nature Medicine*,
427 vol. 21, no. 11, pp. 1350-1356, 2015/11/01 2015, doi: 10.1038/nm.3967.
- 428 [27] B. A. Alves Martins, G. F. de Bulhões, I. N. Cavalcanti, M. M. Martins, P. G. de Oliveira, and
429 A. M. A. Martins, "Biomarkers in Colorectal Cancer: The Role of Translational Proteomics
430 Research," (in eng), *Front Oncol*, vol. 9, p. 1284, 2019, doi: 10.3389/fonc.2019.01284.
- 431 [28] G. W. van Pelt *et al.*, "The tumour-stroma ratio in colon cancer: the biological role and its
432 prognostic impact," (in eng), *Histopathology*, vol. 73, no. 2, pp. 197-206, Aug 2018, doi:
433 10.1111/his.13489.
- 434 [29] K. Zhao *et al.*, "Artificial intelligence quantified tumour-stroma ratio is an independent
435 predictor for overall survival in resectable colorectal cancer," (in eng), *EBioMedicine*, vol. 61,
436 p. 103054, Nov 2020, doi: 10.1016/j.ebiom.2020.103054.
- 437 [30] I. Baraibar *et al.*, "Sex and gender perspectives in colorectal cancer," (in eng), *ESMO Open*,
438 vol. 8, no. 2, p. 101204, Apr 2023, doi: 10.1016/j.esmoop.2023.101204.
- 439 [31] C. H. Li *et al.*, "Sex differences in oncogenic mutational processes," *Nature Communications*,
440 vol. 11, no. 1, p. 4330, 2020/08/28 2020, doi: 10.1038/s41467-020-17359-2.
- 441 [32] X. An, X. Lan, Z. Feng, X. Li, and Q. Su, "Histone modification: Biomarkers and potential
442 therapies in colorectal cancer," *Annals of Human Genetics*, vol. 87, no. 6, pp. 274-284, 2023,
443 doi: <https://doi.org/10.1111/ahg.12528>.
- 444 [33] R. Wang *et al.*, "Histone H4 expression is cooperatively maintained by IKK β and Akt1 which
445 attenuates cisplatin-induced apoptosis through the DNA-PK/RIP1/IAPs signaling cascade,"
446 *Scientific reports*, vol. 7, no. 1, p. 41715, 2017/01/31 2017, doi: 10.1038/srep41715.
- 447 [34] P. Van den Ackerveken *et al.*, "A novel proteomics approach to epigenetic profiling of
448 circulating nucleosomes," *Scientific reports*, vol. 11, no. 1, p. 7256, 2021/03/31 2021, doi:
449 10.1038/s41598-021-86630-3.
- 450 [35] E. ÖZGÜR, M. KESKIN, E. E. YÖRÜKER, S. HOLDENRIEDER, and U. GEZER, "Plasma
451 Histone H4 and H4K20 Trimethylation Levels Differ Between Colon Cancer and

- 452 Precancerous Polyps," *In Vivo*, vol. 33, no. 5, pp. 1653-1658, 2019, doi:
453 10.21873/invivo.11651.
- 454 [36] S. Walrand, R. Lhommel, P. Goffette, M. Van den Eynde, S. Pauwels, and F. Jamar,
455 "Hemoglobin level significantly impacts the tumor cell survival fraction in humans after
456 internal radiotherapy," *EJNMMI Research*, vol. 2, no. 1, p. 20, 2012/05/19 2012, doi:
457 10.1186/2191-219X-2-20.
- 458 [37] W. Yu, G. Chen, J. Yan, X. Wang, Y. Zhu, and L. Zhu, "Single-cell sequencing analysis
459 reveals gastric cancer microenvironment cells respond vastly different to oxidative stress,"
460 *Journal of translational medicine*, vol. 20, no. 1, p. 250, 2022/06/03 2022, doi:
461 10.1186/s12967-022-03411-w.
- 462 [38] E. C. Thomas *et al.*, "Different Characteristics and Nucleotide Binding Properties of Inosine
463 Monophosphate Dehydrogenase (IMPDH) Isoforms," *PLOS ONE*, vol. 7, no. 12, p. e51096,
464 2012, doi: 10.1371/journal.pone.0051096.
- 465 [39] S. Kofuji and A. T. Sasaki, "GTP metabolic reprogramming by IMPDH2: unlocking cancer
466 cells' fuelling mechanism," *The Journal of Biochemistry*, vol. 168, no. 4, pp. 319-328, 2020,
467 doi: 10.1093/jb/mvaa085.
- 468 [40] Y. He *et al.*, "Identification of IMPDH2 as a tumor-associated antigen in colorectal cancer
469 using immunoproteomics analysis," (in eng), *Int J Colorectal Dis*, vol. 24, no. 11, pp. 1271-9,
470 Nov 2009, doi: 10.1007/s00384-009-0759-2.
- 471 [41] Q. Zhang *et al.*, "c-Myc-IMPDH1/2 axis promotes tumourigenesis by regulating GTP
472 metabolic reprogramming," *Clinical and Translational Medicine*, vol. 13, no. 1, p. e1164,
473 2023, doi: <https://doi.org/10.1002/ctm2.1164>.
- 474 [42] S. Duan *et al.*, "IMPDH2 promotes colorectal cancer progression through activation of the
475 PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways," *Journal of Experimental &
476 Clinical Cancer Research*, vol. 37, no. 1, p. 304, 2018/12/05 2018, doi: 10.1186/s13046-018-
477 0980-3.
- 478 [43] S. Peñuelas, V. Noé, and C. J. Ciudad, "Modulation of IMPDH2, survivin, topoisomerase I
479 and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells," *The
480 FEBS Journal*, vol. 272, no. 3, pp. 696-710, 2005, doi: [https://doi.org/10.1111/j.1742-
481 4658.2004.04504.x](https://doi.org/10.1111/j.1742-4658.2004.04504.x).
- 482 [44] L. Théron *et al.*, "A Proof of Concept to Bridge the Gap between Mass Spectrometry Imaging,
483 Protein Identification and Relative Quantitation: MSI~LC-MS/MS-LF," (in eng), *Proteomes*,
484 vol. 4, no. 4, Oct 26 2016, doi: 10.3390/proteomes4040032.
- 485 [45] G. Guo *et al.*, "Automated annotation and visualisation of high-resolution spatial proteomic
486 mass spectrometry imaging data using HIT-MAP," (in eng), *Nat Commun*, vol. 12, no. 1, p.
487 3241, May 28 2021, doi: 10.1038/s41467-021-23461-w.
- 488

489

490 **Statements and Declarations**

491

492 ***Funding***

493 This work was supported by a Cancer Council SA Beat Cancer Infrastructure grant with matched funding
494 support from The Hospital Research Foundation Group (GM. and K.F.). K.F. was supported by a The Hospital
495 Research Foundation Group Early Career Fellowship. C.L. was supported by a University of Adelaide
496 Postgraduate Research Scholarship. The authors acknowledge Bioplatforms Australia, the University of South
497 Australia, and the State and Federal Governments, which co-fund the NCRIS-enabled Mass Spectrometry and
498 Proteomics facility at the University of South Australia.

499

500 ***Competing Interests***

501 The authors have no relevant financial or non-financial interests to disclose.

502

503 ***Author Contributions***

504 Conceptualisation C.L., M.B., M.K.H and K.F.; Collection and/or assembly of data: C.L., M.B., Y.L., T.T.,
505 C.Y., J.P., and G.K. Data Analysis and Interpretation: C.L., M.B., Y.L., C.Y., M.K.H, and K.F., resources: J.P.,
506 G.M., P.H, and K.F.; writing—original draft preparation, C.L., M.B., P.D., M.K.H and K.F.; writing—review
507 and editing, C.L., M.B., C.Y., P.D., M.K.H. and K.F.; supervision, P.H., G.M., M.K.H, and K.F., funding
508 acquisition, C.L., G.M., M.K.H and K.F.; All authors have read and agreed to the published version of the
509 manuscript.

510

511 ***Data Availability***

512 The data underlying this article are available in this published article and its supplementary information files.
513 Additional data are available upon request to the corresponding author.

514

515 ***Ethics Approval***

516 This study was approved by the Human Research Ethics Committee of the Central Adelaide Local Health
517 Network under protocol number 12237.

518

519 ***Consent to Participate***

520 Samples collected were retrospective patient tissues and was not consented as advised by our Human Research
521 Ethics Committee.

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545


546

547

548

549


550 **Figures**



551

552 **Figure 1.** Overview of (A) MALDI-MSI and (B) LC-MS/MS workflows for spatial mapping and
553 characterisation of tryptic peptides from CRLM FFPE tissues (n=84). Created with BioRender.com.

554



555


556

557

558

559

Figure 2. Representative scanned images of (A) H&E CRLM TMA cores, and (B) optical CLRM TMA cores. CRLM tumour regions and CRC tumour regions (control) in (A) were annotated by a pathologist, as shown in black and green, respectively. Scale bars (black lines) represent 3mm.



560


561 **Figure 3.** Identification of tryptic peptides associated with CRLM tumour regions using MALDI-MSI and LC-
 562 MS/MS. (A) Sum spectra of CRLM tumour (red) and (B) stroma (blue) in CRLM tumour cores. (C, D) H&E
 563 images (left) of a representative tumour core with tumour regions annotated in black and ion intensity maps
 564 (right) of most discriminative m/z values between tumour (red) and stroma (red). Tumour cores are 1.5mm in
 565 diameter. Bar graphs showing mean \pm SEM and ROC plots for (E) m/z 1589.876 and (F) m/z 1092.727.
 566 * $p < 0.05$, **** $p < 0.0001$. Student's t test. Each dot represents a single tumour core.

567

568


569

570




571
572
573
574
575
576
577
578
579


580 **Figure 4.** Significantly abundant tryptic peptides associated with male and female CRLM tumour regions, by
581 MALDI-MSI and LC-MS/MS. (A) Representative H&E and ion intensity map of tumour region annotated
582 CRLM tumour cores for m/z 2211.113. Tumour cores are 1.5mm in diameter. (A-D) Tryptic peptides (m/z
583 2211.113, 1296.682, 1570.676, and 1366.628) significantly more abundant in females relative to males. Tryptic
584 peptides were identified as (A) unidentified, (B) Proteasome subunit beta type-9, (C) unidentified, and (D)
585 Trypsin beta-2 Trypsin alpha/beta-1. (E-H) Tryptic peptides (m/z 1669.829, 1461.702, 1466.697, and
586 1235.618) significantly more abundant in males relative to females. These tryptic peptides were identified as (E)
587 unidentified, (F) Carcinoembryonic antigen-related cell adhesion molecule 5, (G) Heat shock cognate 71 kDa
588 protein, and (H) unidentified. Bar graphs showing mean \pm SEM and ROC plots are presented. **** $p < 0.0001$.
589 Student's t test. Each dot represents a single tumour core.
590



591
592
593
594
595
596
597
598
599
600

601 **Figure 5.** Significantly abundant tryptic peptides associated with male and female CRLM stroma regions, by
602 MALDI-MSI and LC-MS/MS. (A) Representative H&E and ion intensity map of stroma region annotated
603 CRLM tumour cores for m/z 1366.628. Tumour cores are 1.5mm in diameter. (A-F) Tryptic peptides (m/z
604 1366.628, 1296.682, 2211.113, 1570.676, 1661.060 and 1305.840) significantly more abundant in females
605 relative to males. Tryptic peptides were identified as (A) Tryptase beta-2 Tryptase alpha/beta-1, (B) Proteasome
606 subunit beta type-9, and (C-F) unidentified. (G-H) Tryptic peptides (m/z 1669.829 and 1461.702) significantly
607 more abundant in males relative to females. These tryptic peptides were identified as (G) unidentified and (H)
608 Carcinoembryonic antigen-related cell adhesion molecule 5. Bar graphs showing mean \pm SEM and ROC plots
609 are presented. **** $p < 0.0001$. Student's t test. Each dot represents a single tumour core.
610





612

613 **Figure 6.** Significantly abundant tryptic peptides associated with poor overall survival (0-3 years) in CRLM
 614 tumour regions. CRLM cores were subdivided based on overall survival after curative-intent surgery (0-3, 4-6,
 615 and 7+ years). Representative H&E and ion intensity maps of tumour region annotated CRLM tumour cores for
 616 m/z 1325.754, 1529.738, 1481.857, 1305.840, and 1661.060. Tumour cores are 1.5mm in diameter. These
 617 tryptic peptides were identified as (A) Histone H4, (B) Haemoglobin subunit alpha, (C) Inosine-5'-
 618 monophosphate dehydrogenase 2 and (D-E) unidentified by LC-MS/MS. Bar graphs showing mean \pm SEM and
 619 ROC plots are presented. $*p < 0.05$, $**p < 0.01$. Ordinary one-way ANOVA. Each dot represents a single tumour
 620 core.

621

622

623

624

625

626

627

628

629

630

631

632

633 **Tables**

634

635 **Table 1. Demographic and clinicopathological characteristics of Australian CRLM patient cohort (n=84).**

Patients	n = 84
Age	
Median age	67
Age range	33-88
Early onset <50	6 (7.1%)
Late onset >50	68 (80.9%)
Missing	10 (11.9%)
Sex	
Female	25 (29%)
Male	59 (70%)
Overall survival (years)	
Median [Min, Max]	3.75 [0.36-11.94]
Mean (SD)	4.51 (2.9)
Survival groups	
0-3 years	25 (29.7%)
4-6 years	24 (28.6%)
7+ years	35 (41.7%)

Table 2. Tryptic peptides and proteins that discriminate between tumour and stroma regions in CRLM by MALDI-MSI and LC-MS/MS.

No.	<i>m/z</i> Measured by MALDI-MSI	MALDI-MSI AUC (Tumour vs Stroma)	<i>p</i> -value	Enriched in Tumour vs Stroma	<i>m/z</i> Measured by LC-MS/MS	<i>m/z</i> Charge State (+2, +3)	Tryptic Peptide Sequence Confirmed by LC-MS/MS	Theoretical Singly Charged Tryptic Peptide <i>m/z</i>	<i>m/z</i> Error (ppm)	Protein Identified	Accession No.	Protein Coverage (%)
1	1589.876	0.618	<0.0001*	Tumour	Unidentified							
2	1092.727	0.562	<0.050*	Tumour	Unidentified							
3	1305.840	0.558	0.053	-	Unidentified							
4	1529.738	0.545	0.135	-	510.583	+3	VGAHAGEYGAEALER	1529.734	+2.6	Haemoglobin subunit alpha	P69905	71.1
5	1661.060	0.553	0.079	-	Unidentified							
6	1368.638	0.544	0.147	-	Unidentified							
7	1198.710	0.536	0.233	-	599.856	+2	AVFPSIVGRPR	1198.706	+3.3	Actin, cytoplasmic 1 Actin, cytoplasmic 2	P60709 P63261	59.2 59.2
8	1292.665	0.529	0.337	-	646.840	+2	DLQFVEVTDVK	1292.673	-6.2	Fibronectin	P02751	9.4
9	1585.772	0.531	0.053	-	Unidentified							
10	1591.817	0.531	0.531	-	796.407	+2	EGYLQIGANTQAAQK	1591.807	+6.3	Liver carboxylesterase 1	P23141	27.0
11	1641.805	0.525	0.414	-	821.402	+2	VDTNAPDLSLEGPEGK	1641.797	+4.9	Neuroblast differentiation-associated protein AHNAK	Q09666	31.7
12	1706.776	0.527	0.371	-	853.899	+2	EGPVQFEEDPFGLDK	1706.791	-8.8	SNW domain-containing protein 1	Q13573	2.8

13	1280.719	0.521	0.485	-	640.864	+2	TEVIPPLIENR	1280.721	-1.6	Apolipoprotein B-100	P04114	0.5
14	1481.857	0.528	0.355	-	494.628	+3	REDLVVAPAGITLK	1481.869	-8.1	Inosine-5'-monophosphate dehydrogenase 2	P12268	4.5
15	1954.064	0.524	0.426	-	652.026	+3	VAPEEHPVLLTEAPLNPK	1954.064	0.0	Actin, cytoplasmic 1 Actin, cytoplasmic 2	P60709 P63261	59.2 59.2
16	2056.984	0.521	0.481	-	686.327	+3	LAEQAERYDEMVESMK K	2056.968	+7.8	14-3-3 protein epsilon	P62258	45.5
17	2211.113	0.532	0.287	-	Unidentified							
18	1325.754	0.513	0.680	-	663.380	+2	DNIQGITKPAIR	1325.754	0.0	Histone H4	P62805	54.4
19	1465.690	0.503	0.908	-	733.350	+2	SDLVNEEATGQFR	1465.692	-1.4	Carcinoembryonic antigen-related cell adhesion molecule 5	P06731	14.0
20	1833.902	0.500	0.996	-	611.979	+3	VFSNGADLSGVTEEAPL K	1833.923	-11.5	Alpha-1-antitrypsin	P01009	34.0

* Indicates statistically significant differences.

637

638

639

640

641

642

643

644

Table 3. Tryptic peptides and proteins that discriminate between biological sex in CRLM by MALDI-MSI and LC-MS/MS.

No.	<i>m/z</i> Measured by MALDI-MSI	MALDI-MSI AUC Stroma (Male vs Female)	<i>p</i> -value	Stroma Enriched (Male vs Female)	MALDI-MSI AUC Tumour (Male vs Female)	<i>p</i> -value	Tumour Enriched (Males vs Female)	<i>m/z</i> Measured by LC-MS/MS	<i>m/z</i> Charge State (+2, +3)	Tryptic Peptide Sequence Confirmed by LC-MS/MS	Theoretical Singly Charged Tryptic Peptide <i>m/z</i>	<i>m/z</i> Error (ppm)	Protein Identified	Accession No.	Protein Coverage (%)
1	2211.113	0.633	0.0139*	Female	0.695	<0.0001*	Female	Unidentified							
2	1296.682	0.662	0.0053*	Female	0.687	<0.0001*	Female	648.834	+2	FTTDAIALAMSR	1296.662	+15.4	Proteasome subunit beta type-9	P28065	18.30
3	1570.676	0.645	0.0077*	Female	0.689	<0.0001*	Female	Unidentified							
4	1669.829	0.661	0.0029*	Male	0.683	<0.0001*	Male	Unidentified							
5	1461.702	0.563	0.2489	-	0.612	0.0064*	Male	Unidentified							
6	1465.697	0.638	0.0108*	Male	0.611	0.0072*	Male	733.350	+2	SDLVNEEATGQFR	1465.692	+3.4	Carcinoembryonic antigen-related cell adhesion molecule 5	P06731	14.0
7	1235.618	0.582	0.132	-	0.605	0.0111*	Male	618.316	+2	MVNHFAIEFK	1235.624	-4.9	Heat shock cognate 71 kDa protein	P11142	31.30
8	1366.628	0.677	0.0011*	Female	0.601	0.0145*	Female	683.823	+2	YHLGAYTGDDVR	1366.639	-8.0	Tryptase beta-2 Tryptase alpha/beta-1	P20231 Q15661	24 24
9	1481.857	0.558	0.2874	-	0.551	0.2128	-	494.628	+3	REDLVVAPAGITLK	1481.869	-8.1	Inosine-5'-monophosphate dehydrogenase 2	P12268	4.5
10	1280.719	0.549	0.3971	-	0.550	0.2247	-	640.864	+2	TEVIPPLIENR	1280.721	-1.6	Apolipoprotein B-100	P04114	0.5
11	1441.676	0.557	0.2972	-	0.547	0.2542	-	721.343	+2	EFTPQMQAAYQK	1441.678	-1.4	Hemoglobin subunit delta	P02042	40.10
12	1661.060	0.639	0.0105*	Female	0.520	0.6212	-	Unidentified							
13	1305.840	0.650	0.0056*	Female	0.505	0.8958	-	Unidentified							
14	1529.738	0.557	0.2972	-	0.502	0.9697	-	510.583	+3	VGAHAGEYGAEALER	1529.734	+2.6	Hemoglobin subunit alpha	P69905	71.1

645

* Indicates statistically significant differences.

646 **Table 4. Tryptic peptides and proteins that discriminate overall survival identified by MALDI-MSI and LC-MS/MS.**

No.	<i>m/z</i> Measured by MALDI-MSI	MALDI-MSI AUC Tumour (0-3 vs 7+ Years)	<i>p</i> -value	MALDI-MSI AUC Tumour (0-3 vs 4-6 Years)	<i>p</i> -value	MALDI-MSI AUC Tumour (4-6 vs 7+ Years)	<i>p</i> -value	<i>m/z</i> Measured by LC-MS/MS	<i>m/z</i> Charge State (+2, +3)	Tryptic Peptide Sequence Confirmed by LC-MS/MS	Theoretical Tryptic Peptide <i>m/z</i>	<i>m/z</i> Error (ppm)	Protein Identified	Accession No.	Protein Coverage (%)
1	1325.754	0.720	<0.0001*	0.547	0.3736	0.644	0.0132*	442.589	+3	DNIQGITKPAIR	1325.754	0.0	Histone H4	P62805	54.4
2	1529.738	0.654	0.0031*	0.574	0.1602	0.594	0.1059	765.371	+2	VGAHAGEYGAEALER	1529.734	+2.6	Hemoglobin subunit alpha	P69905	71.1
3	1481.857	0.624	0.0016*	0.573	0.1157	0.540	0.3445	494.628	+3	REDLVVAPAGITLK	1481.869	-8.1	Inosine-5'-monophosphate dehydrogenase 2	P12268	4.5
4	1305.840	0.616	0.003*	0.558	0.211	0.551	0.2245	Unidentified							
5	1661.060	0.609	0.005*	0.555	0.2307	0.526	0.5366	Unidentified							
6	1589.876	0.594	0.0696	0.552	0.3281	0.665	0.0045*	Unidentified							

647 * Indicates statistically significant differences.

648

649

650

651

652